Tags : Metastatic Hormone-Sensitive Prostate Cancer

Astellas Reports Results of Xtandi (enzalutamide) in P-III ARCHES Trial

Vartika Singh February 12, 2019

Shots: The P-III ARCHES trial involves assessing of Xtandi + ADT (enzalutamide, 160mg) vs ADT monothx in 1,150 men with mHSPC at the US, Canada, EU, South America P-III ARCHES […]readmore

Tags : Metastatic Hormone-Sensitive Prostate Cancer

Astellas Reports Results of Xtandi (enzalutamide) in P-III ARCHES Trial

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Metastatic Hormone-Sensitive Prostate Cancer

Astellas Reports Results of Xtandi (enzalutamide) in P-III ARCHES Trial

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company